Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) and minimally treated patients (MTPs) < 6 years with severe hemophilia A (FVIII < 1%)

Trial Profile

Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) and minimally treated patients (MTPs) < 6 years with severe hemophilia A (FVIII < 1%)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 May 2017

At a glance

  • Drugs Rurioctocog alfa pegol (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BAX855 PUP study
  • Sponsors Baxalta
  • Most Recent Events

    • 01 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top